Skip to main content
    B

    Bristol-Myers Squibb Company (BMY)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $62.94
    -0.49 (-0.77%)

    Market Cap: $129.66B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Bristol-Myers Squibb Company (BMY) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Bristol-Myers Squibb Company (BMY) to earn $6.44 per share in the fiscal year ending Dec 31, 2026, on revenue of $50.23B. Of 28 analysts, 10 rate the stock Buy or Strong Buy, 17 Hold and 1 Sell or Strong Sell, for a consensus of Hold. For the fiscal year ending Dec 31, 2027, the EPS consensus is $6.70.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.54, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 36% of the ratings.

    RatingAnalystsShare
    Strong Buy414.3%
    Buy621.4%
    Hold1760.7%
    Sell13.6%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    28

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 4.0% and revenue estimates fall 2.8%.

    Fiscal year ending Dec 31, 2026
    $6.44
    EPS consensus, revenue $50.23B
    Fiscal year ending Dec 31, 2027
    $6.70
    EPS consensus, revenue $48.80B
    Next report
    Feb 3, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$6.44$6.18 to $6.5727$50.23B$49.95B to $50.60B24
    Dec 31, 2027$6.70$5.72 to $7.5628$48.80B$46.94B to $50.17B26

    Quarterly Estimates

    The EPS consensus rises from $1.50 for the quarter ending Dec 31, 2026 to $1.52 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$1.50$1.29 to $1.6925$12.80B$12.17B to $13.68B23
    Mar 31, 2027$1.52$1.31 to $1.689$11.17B$10.64B to $11.37B6

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 20 upward and 8 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 2027177
    Quarter ending Mar 31, 202731

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 7.3% from $6.95.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$6.44$6.44$6.77$6.95$6.95-7.3%
    Fiscal year ending Dec 31, 2027$6.70$6.66$6.60$6.56$6.56+2.2%
    Quarter ending Mar 31, 2027$1.52$1.51$1.47$1.45$1.45+5.0%

    Frequently Asked Questions About BMY

    What is the BMY stock forecast?

    Consensus analyst estimates put Bristol-Myers Squibb Company's EPS at $6.44 for the fiscal year ending Dec 31, 2026, on revenue of $50.23B. The consensus rating from 28 analysts is Hold.

    How do analysts rate BMY stock?

    Of 28 analysts covering Bristol-Myers Squibb Company, 4 rate it Strong Buy, 6 Buy, 17 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from BMY next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $6.44, with estimates from $6.18 to $6.57 from 27 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $6.70, with estimates from $5.72 to $7.56 from 28 analysts.

    What revenue do analysts expect from Bristol-Myers Squibb Company next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $50.23B, with estimates from $49.95B to $50.60B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $48.80B, with estimates from $46.94B to $50.17B.

    How many analysts cover BMY?

    28 analysts rate Bristol-Myers Squibb Company stock, and 27 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.